Teva Pharmaceuticals Australia Pty Ltd

Tetsuya Taura

Sarah Lee Pogue

David S Wilson, Jr

Anthony Gerard Doyle

Adam Clarke

Matthew Pollard

Glen Eugene Mikesell

Wouter Korver

Collette Behrens

David S Wilson

Stephen Tran

Jack Tzu Chiao Lin

Tetsuo Yamagishi

David Wilson

Jack Tzu-Chiao Lin

Adam W Clarke

Anthony G Doyle

Jr David S Wilson

Antony G Doyle

The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRPα receptor.

Anti-CD47 combination therapy

The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type 1 interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRP&#x3b1; receptor.

Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Fusions of antibodies to CD38 and attenuated interferon alpha

The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.

Modified antibody with improved half-life

Growing community of inventors

Palo Alto, CA, United States of America

Tetsuya Taura